- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
FDA Accepts Ranibizumab BLA From Samsung Bioepis and Biogen
The FDA's acceptance of the biologics license application (BLA) moves the companies one step closer to entering the US ophthalmology treatment sphere with a biosimilar.
Samsung Bioepis and Biogen said the FDA has accepted for review their biologics license application for a ranibizumab biosimilar candidate (SB11), referencing Lucentis, a Genentech product. The drug is an anti–vascular endothelial growth factor treatment for retinal vascular disorders, a leading cause of blindness.
SB11 was developed by Samsung Bioepis and Biogen is the commercialization partner, according to an agreement the companies signed in November 2019.
“The FDA filing acceptance for SB11 brings us a step closer to our goal of being able to offer affordable treatment options for people with retinal vascular disorders,” said Hee Kyung Kim, senior vice president and Clinical Sciences Division and Regulatory Affairs team leader for Samsung Bioepis.
The European Medicines Agency accepted the marketing application for SB11 in October 2020. The corporate partners already market several biosimilars on the European market, including an etanercept (Benepali), adalimumab (Imraldi), and infliximab (Flixabi).
Samsung Bioepis and Biogen also plan to bring an aflibercept biosimilar (SB15) to market in the United States, Canada, Europe, Japan, and Australia. In the United States, aflibercept (Eylea) is indicated for the treatment of macular degeneration, macular edema, and diabetic retinopathy.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.
Biosimilars Development Roundup for October 2024—Podcast Edition
November 3rd 2024On this episode of Not So Different, we discuss the GRx+Biosims conference, which included discussions on data transparency, artificial intelligence (AI), and collaboration to enhance the global supply chain for biosimilars and generic drugs, as well as the evolving requirements for biosimilar devices.
Insights from Festival of Biologics: Dracey Poore Discusses Cardinal Health’s 2024 Biosimilar Report
May 19th 2024The discussion highlights key emerging trends from the Festival of Biologics conference and the annual Cardinal Health Biosimilars Report, including the importance of sustainability in the health care landscape and the challenges and successes in biosimilar adoption and affordability.
Breaking Down Biosimilar Barriers: Interchangeability
November 14th 2024Part 3 of this series for Global Biosimilars Week, penned by Dracey Poore, director of biosimilars at Cardinal Health, explores the critical topic of interchangeability, examining its role in shaping biosimilar adoption and the broader implications for accessibility.
Eye on Pharma: Henlius, Organon Updates; Meitheal Portfolio Expansion; Celltrion Zymfentra Data
November 5th 2024Henlius and Organon’s pertuzumab biosimilar met phase 3 goals; Meitheal expanded its US biosimilars; Celltrion’s subcutaneous infliximab (Zymfentra) showed monotherapy could be as effective as combination therapy for inflammatory bowel disease.
